Registration: 144A/Reg S; Comments: EUR575m (from EUR400m minimum size) due 01/15/28 (7.25y). NC3.25 (01/15/24) (MWC B+50bp), Then at 102.187, 101.094, 100. Equity claw: 3.25y 40% at 104.375. Special call: 10% per year the first 3.25 years at 103. Reg S ISIN: XS2243548273. IPT mid-to-high 4s. Px talk: 4.50% area. Launched: EUR575m at 4.375%. Priced: 4.375% at 100. +504bp vs DBR 5.625% 01/04/28.;
Registration: 144A/Reg S; Comments: USD500m (from USD500m minimum size) due 2028 (7.25y). NC3.25 (MWC T+50bp) (50%, 25%, par). Equity claw: 3.25y 40%. IPT 6% area. Px talk: 5.75% area. Revised price talk: $500m at 5.50%-6.625%.;
Deal Comments
Cheplapharm Arzneimittel GmbH (CHEPDE) EUR1bn equivalent (EUR/US$) 144A/Reg S sr sec 1st lien notes 2-part. B2/B/BB- (negative/stable/stable). Via JPM/DB joint glocos/CS/HSBC joint books. No reg rights. List ISE. NY law.
- EUR575m (from EUR400m minimum size) due 2029 (7.25y). NC3.25 (MWC B+50bp) (50%, 25%, par). Equity claw: 3.25y 40%. IPT mid-to-high 4s. Px talk: 4.50% area. Launched: EUR575m at 4.375%.
- USD500m (from USD500m minimum size) due 2028 (7.25y). NC3.25 (MWC T+50bp) (50%, 25%, par). Equity claw: 3.25y 40%. IPT 6% area. Px talk: 5.75% area. Revised price talk: $500m at 5.50%-6.625%.
Roadshow 10/05-07 (European investor call at 11am UKT 10/05, US investor call at 12:30pm NYT 10/05). EUR books closed at 10am UKT 10/08. US books now close at 10am 10/08 (originally closing at 5pm NYT 10/07). Pricing 10/08. UOP: along with EUR90m cash on hand and a EUR50m revolver drawdown, to fund acquisitions (cardiology portfolio form Sanofi for EUR93m, portfolio of 4 products from LEO Pharma for EUR302m, portfolio of products from Takeda for EUR475m and Rivotril from Roche for EUR260m). Biz: specialty pharmaceuticals. HQ: Greifswald, Germany.
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.